Abstract
Tobacco smoking is a bladder cancer risk factor and a source of carcinogens that induce DNA damage to urothelial cells. Using data and samples from 988 cases and 1,004 controls enrolled in the Los Angeles County Bladder Cancer Study and the Shanghai Bladder Cancer Study we investigated associations between bladder cancer risk and 632 tagSNPs that comprehensively capture genetic variation in 28 DNA repair genes from four DNA repair pathways: base excision repai, nucleotide excision repair (NER), non-homologous end-joining (NHEJ), and homologous recombination repair (HHR). Odds ratios (ORs) and 95% confidence intervals (CIs) for each tagSNP were corrected for multiple testing for all SNPs within each gene using pACT, and for genes within each pathway and across pathways with Bonferroni. Gene and pathway summary estimates were obtained using ARTP. We observed an association between bladder cancer and POLB rs7832529 (BER) (pACT = 0.003; ppathway = 0.021) among all, and SNPs in XPC (NER) and OGG1 (BER) among Chinese men and women, respectively. The NER pathway showed an overall association with risk among Chinese males (ARTP NER p = 0.034). The XRCC6 SNP rs2284082 (NHEJ), also in LD with SREBF2, showed an interaction with smoking (Smoking status interaction pgene = 0.001, ppathway = 0.008, poverall = 0.034). Our findings support a role in bladder carcinogenesis for regions that map close to or within BER (POLB, OGG1) and NER genes (XPC). A SNP that tags both the XRCC6 and SREBF2 genes strongly modifies the association between bladder cancer risk and smoking.
Keywords: Bladder cancer, smoking, DNA repair, POLB, XRCC6
INTRODUCTION
Urinary bladder cancer is among the 10 most common cancers worldwide, with its age standardized incidence rate varying by gender and world regions1. In Los Angeles County non-Hispanic white men have the highest incidence rate of bladder cancer, followed by Hispanic, African-American and Asian-American men, in spite of comparable profiles of tobacco use. Women show a similar pattern of incidence rates by race, although the overall rates are much lower than men2. Chinese from Shanghai have about two-third the incidence rate of bladder cancer of Chinese in Los Angeles3. Cigarette smoking and occupational exposure to arylamines are the main established risk factors4. Tobacco smoking contributes upwards of 50% of bladder cancer occurrence in men and 20% in women5; although more recent data suggests that in the US the population attributable risk of smoking among men and women might now be comparable6. In addition to smoking and occupational exposure to arylamines7, use of hair dyes has been identified as a bladder cancer risk factor8.
Chemical carcinogens present in tobacco smoke, such as polycyclic aromatic hydrocarbons, aromatic amines, heterocyclic amines, and N-nitroso compounds, and arylamines from other sources, can induce DNA damage in the bladder epithelium9. In addition, reactive oxygen species (ROS) present in tobacco smoke10, and also generated as a by-product of chemical carcinogen metabolism11, 12, can contribute to additional DNA damage. Altogether, chemical carcinogens and ROS can contribute to the accumulation of bulky adducts, single (SSB), and double strand breaks (DSB), and various forms of nucleotide base modification or loss which can lead to genomic instability. Modified or lost bases and SSBs are generally repaired through the base excision repair pathway (BER). DSBs are repaired by either the non-homologous end joining (NHEJ) or the homologous recombination repair (HRR) pathways. Bulky adducts are repaired by the nucleotide excision repair (NER) pathway.
Given the important role DNA repair pathways play in maintaining DNA integrity, it has been postulated that inter-individual genetic variation in these pathways may modify bladder cancer risk. Consistent with this hypothesis, individuals with reduced DNA repair proficiency were reported to have higher risk of developing bladder cancer13. Several epidemiological studies have investigated the bladder cancer associations with candidate polymorphisms in selected DNA repair genes, and a large pooled and meta-analysis of most of these studies offered support for a role of selected DNA repair variants in bladder carcinogenesis14. More recently, a comprehensive analysis of the NER pathway was conducted which offered further support for a role for DNA repair variants in bladder cancer risk15.
In this study, we report findings from an extensive pathway-based examination of 632 haplotype-tagging SNPs selected to examine common variation in coding and non-coding regions across 27 DNA repair-related genes, belonging to four DNA repair pathways: BER (APEX1, LIG3, NEIL1, OGG1, PARP1, POLB, XRCC1), NER (ERCC1, ERCC2, ERCC4, ERCC5, LIG1, POLD1, XPA, XPC), NHEJ (DCLRE1C, LIG4, PRKDC, XRCC4, XRCC5, XRCC6), and HRR (MRE11A, NBN, RAD50, RAD51, RAD52, XRCC2, XRCC3). We conducted these analyses using data from two parallel case-control studies that were similarly designed and carried out in areas of high and low bladder cancer risk: the Los Angeles Bladder Cancer Study and the Shanghai Bladder Cancer Study. We considered the potential modifying role of DNA repair SNPs on the association of gender and smoking with bladder cancer risk.
Materials and Methods
Study population
Study participants were enrolled as part of two population-based case-control studies of transitional cell carcinoma of the urinary bladder conducted in Los Angeles County, California, USA and Shanghai, China. Characteristics of the Los Angeles Bladder Cancer (LABC) and Shanghai Bladder Cancer (SBC) studies have been described previously16, 17. Briefly, the Los Angeles County Cancer Surveillance Program was used to identify cases diagnosed with histologically confirmed bladder cancer, among non-Asian cases between the ages of 25 and 68 years of age from 1987 through 1996. Using a standard procedure16, controls were identified among residents of the cases' neighborhoods of residence and individually (1:1) matched to cases by gender, race/ethnicity and age (±5 years). In Shanghai, the Shanghai Cancer Registry was used to identify cases diagnosed with histologically confirmed bladder cancer, residents of the city of Shanghai and between the ages of 25 and 74 years of age from 1995–1998. A previously described algorithm was used to randomly identify population-based controls from within the city of Shanghai18, who were frequency matched to bladder cancer cases by gender and 5 year age groups. In-person questionnaires administered to all study participants were used to collect demographic, lifestyle, and medical characteristics up to up to reference date, which in Los Angeles was defined for each case-control pair as two years before the case's diagnosis and in Shanghai was defined as two years prior to diagnosis for cases and two years prior to interview for controls. Mean time interval between bladder cancer diagnosis and interview was 11 months for bladder cancer cases in Los Angeles County, and 7 months for bladder cancer cases in Shanghai16, 17. Blood specimens were collected at the time of interview. Analyses in the current study were restricted to 936 non-Hispanic Whites (NHW) from Los Angeles County (456 cases and 480 controls) and 1,056 Han Chinese from Shanghai (532 cases and 524 controls) with DNA and questionnaire data. The study was approved by Institutional Review Boards at the University of Southern California, the Shanghai Cancer Institute and the University of Pittsburgh.
Tagging SNP selection
Tagging SNPs (tagSNPs) for each DNA repair gene region were selected using Snagger19, based on the HapMap CEPH (Utah residents with Northern and Western European Ancestry (CEU)) population and Han Chinese in Beijing, China (CHB) population using data from HapMap release 21, July 2006. TagSNPs were selected using the following criteria: minor allele frequency (MAF) ≥ 5%, pairwise r2 ≥ 0.80, and a distance from the closest SNP greater than 60 base pairs on the Illumina platform. For each gene, the 5′ -UTR- and 3′ -UTR regions were extended to include SNPs ~20 kb upstream and ~10 kb downstream. In regions of no or low LD, tagSNPs with a MAF ≥ 5% at a density of ~ 1 per kb were selected from either HapMap or dbSNP. Finally, non-synonymous tagSNPs and selected investigator selected SNPs were included regardless of the MAF. With the tagging approach used we were able to capture on average 95.6% (range from 83%–100%) of genetic variation in CEU and 96.2% (range from 85% – 100%) in CHB, when considering the HapMap release 21, July 2006. This coverage is likely to be lower if we considered the more recent 1000 Genomes as reference panel.
SNP genotyping and quality control
Peripheral blood lymphocytes were subjected to proteinase K digestion, phenol-chloroform extraction and ethanol precipitation for the purpose of DNA extraction. SNPs were genotyped on the Illumina GoldenGate BeadArray genotyping platform20 (Illumina, Inc., San Diego, CA, USA) at the Genomics Core of the USC Norris Comprehensive Cancer Center. The Bead Studio software program was used to cluster and call genotypes according to standard Illumina protocols. In addition to Illumina QC measures, cases and controls were mixed on genotyping plates and blinded duplicate samples were included. The observed concordance for duplicate samples was >99%. Genotype data from 30 CEPH trios (Coriell Cell Repository, Camden, NJ) was also used to confirm genotyping reliability and reproducibility. TagSNPs were excluded if more than 3 discordant genotypes were found in comparison with genotypes from the International HapMap Project.
Further stringent criteria were applied to ensure quality genotyping data. We required that all SNPs have call rates ≥ 0.90 for the combined LABC-SBC study after eliminating SNPs which failed completely. Of the 632 SNPs, 5 SNPs were eliminated due to call rates of 0%. Supplementary Table 1 describes all 627 SNPs in this study, including their minor allele frequencies among NHW and Chinese control populations. Analyses that stratified on race were restricted to SNPs with MAF ≥ 5% among Los Angeles controls (545 SNPs) or SNPs with MAF ≥ 5% among Shanghai controls (542 SNPs). Combined analyses of LABC and SBC were restricted to SNPs with MAF ≥ 5% among controls from both study sites (469 SNPs). We required all individuals had overall call rates ≥ 90% and excluded from analyses 192 individuals with overall call rates less than 90%. After excluding subjects with call rates less than 90%, we had genotyping results available for 1,800 individuals out of a total of 1,992. Individuals with genotyping data did not differ significantly from those without genotyping data for key characteristics, such as those listed in Table 1.
Deviations of observed genotype frequencies from those expected under Hardy-Weinberg equilibrium (HWE) were examined among Los Angeles and Shanghai controls separately using exact tests. The p-value when testing deviations of observed genotype frequencies from those expected under HWE was deemed significant if p < 0.00008 using exact tests (Bonferroni-corrected p-value; α = 0.05/627). We did not observe evidence of deviations of observed from expected values among Los Angeles non-Hispanic white controls or Shanghai Chinese controls.
Statistical analysis
SNP main effects
In order to include all available individuals in our study, regardless of availability of 1:1 matched controls, we grouped individuals according to their reference age (<45, 45–49, 50–54, 55–59 and ≥60 years for Los Angeles non-Hispanic whites and <45, 45–49, 50–54, 55–59, 60–64 and ≥65 years for Shanghai Chinese), gender and study site and used it to group individuals in conditional logistic regression models used to estimate relative risks with odds ratios (ORs) and 95% confidence intervals (95%CI). Assuming a log-additive mode of action, we estimated per-allele ORs and 95%CI for the associations between each tagSNP and bladder cancer. Models were adjusted for smoking status (never/quit/current) in the reference year. Analyses were conducted separately by study site and jointly with adjustment for study site; we assessed for potential heterogeneity of SNP main effects across both study sites using likelihood ratio tests. Given the observed disparities in bladder cancer incidence between males and females, both in Los Angeles and Shanghai, we hypothesized that different environmental risk factors could associate with each gender. If some of these risk factors contribute to bladder carcinogenesis through the accumulation of DNA damage, we speculated that we could observe different associations between DNA repair SNPs and bladder cancer for males and females. To test this hypothesis we assessed potential heterogeneity of SNP main effects by gender using likelihood ratios tests.
Multiple testing was conducted in a hierarchical bottom-up manner. We first corrected for multiple SNP tests within each gene region, then for multiple genes within the corresponding DNA repair pathway, and finally across all four DNA repair pathways investigated. Specifically, for each SNP within each gene region, crude p-values (pcrude) were corrected for multiple testing using the PACT (p-value adjusted for correlated tests) approach, implemented within R21.. We corrected for overall significance across gene regions within each pathway (ppathway) using a Bonferroni correction of the PACT corrected p-value. Finally, we further corrected for overall statistical significance across all 4 investigated pathways (poverall) using a Bonferroni correction of the pathway specific (ppathway) p-value.
Pathway analyses
In order to capture gene and pathway level effects that may not be detectable through any single SNP, we performed gene-based and pathway-based tests using the Adaptive Rank-Truncated Product (ARTP) method22. ARTP adaptively combines single SNP p-values within a gene-region or a pathway to obtain a single test statistic for the gene or pathway and assesses significance of the test via a permutation procedure. Unlike a multiple testing procedure like PACT, which accounts for multiple SNP tests in order to properly control the type I error, ARTP combines information across SNPs within a gene or a pathway in order to increase the power to detect a gene or pathway level effect.
SNP-Smoking interactions
We investigated SNP-smoking interactions considering the following smoking variables: smoking status (never, former, current), smoking intensity (never, < 20, ≥20 cigarettes per day), smoking duration (never, < 29, ≥ 29 years of smoking), and pack-years of smoking (never, < 24, ≥ 24 pack-years). Three level variables were generated using the median value among smoking controls as a cut point for cigarettes per day, years of smoking, and pack-years. Interactions between SNPs and exposures were investigated on a multiplicative scale using conditional logistic models, assuming a log-additive mode of risk and using likelihood ratio tests that included product terms between each tagSNP and a three level exposure variable coded with dummy variables. Tests of trend across categories of exposure were conducted by assigning median values to every tertile of exposure and modeling the categories as continuous. Interaction between SNPs and smoking status assumed smoking status (Never = 0, quit= 1, current = 2) was a categorical variable in the interaction model, while the p-values for trend were calculated assuming smoking status as continuous in the interaction model.
Similar to our hierarchical approach for multiple testing correction for SNP main effects, within each gene region, crude interaction p-values for each SNP (interaction pcrude) were adjusted using a Bonferroni correction (PACT supports multiple tests of SNP main effects but not multiple tests of SNP by exposure interactions) that considered the number of SNPs investigated within each corresponding gene region (interaction pgene). These corrected interaction p-values were further adjusted using a Bonferroni correction for the number of gene regions within each specific pathway (interaction ppathway). Finally, these corrected interaction p-values were further adjusted using Bonferroni for pathway-wide significance (interaction poverall), considering that a total of 4 pathways had been investigated. In all levels of correction, statistical significance was declared if corrected p-values were < 0.05. All statistical tests conducted were two sided and all analyses were performed using Stata 11/SE (Stata Corporation, College Station, TX) and the statistical package R 2.15 (The R Project for Statistical Computing, http://www.r-project.org).
RESULTS
Characteristics of cases and controls are summarized in Table I. Briefly, males accounted for approximately 80% of study participants in both Los Angeles County and Shanghai. Mean age at enrollment for cases was 56 years of age in Los Angeles County and 64 years of age in Shanghai. While 44% of Shanghai cases were older than 65 years of age, less than 1% of Los Angeles cases were older than 65 years of age. Reported rates of cigarette smoking were higher among Los Angeles County cases and controls than among Shanghai cases and controls.
DNA repair SNPs and bladder cancer risk
We investigated associations between DNA repair tagSNPs and bladder cancer risk among NHW from the LABCS and Chinese from the SBCS, separately and combined. Among the 545 tagSNPs investigated among NHW in the LABC study 21 showed statistically significant associations with bladder cancer (pcrude < 0.05); however, none remained significant after within gene region correction (pACT > 0.05). None of these 21 tagSNPs showed statistically significant associations among Shanghai Chinese (Supplementary Table I).
Among the 542 tagSNPs investigated among Shanghai Chinese, 30 tagSNPs were statistically significantly associated with bladder cancer (pcrude < 0.05), and five of them remained statistically significant after multiple comparisons adjustment within gene region (PACT < 0.05): one in the POLB gene (rs7832529, OR = 1.5; 95% CI = 1.2–1.9; pACT = 0.003), one in the POLD1 gene (rs2244095, OR = 0.8; 95%CI = 0.6–0.9; pACT = 0.025), and three in the XPC gene (rs2607734, OR = 1.3, 95% CI = 1.1–1.6, pACT = 0.020; rs2279017, OR = 1.3; 95%CI = 1.1–1.6, pACT = 0.024; rs2228001, OR = 1.3, 95%CI = 1.1–1.6, pACT = 0.028) (Table 2).
Table 2.
Pathway | Gene | tagSNP | MAF | Ca | Co | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | pHet |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||
NHW (LABC) | |||||||||||||
BER | POLB | rs7832529 | 0.05 | 351 | 405 | 1.4 | 0.9 | 2.1 | 0.186 | 0.662 | 1.000 | 1.000 | |
NER | POLD1 | rs2244095 | 0.11 | 353 | 407 | 0.9 | 0.6 | 1.2 | 0.473 | 0.884 | 1.000 | 1.000 | |
NER | POLD1 | rs2546551 | 0.44 | 353 | 404 | 0.8 | 0.7 | 1.0 | 0.066 | 0.354 | 1.000 | 1.000 | |
NER | XPC | rs2607734 | 0.43 | 355 | 409 | 1.0 | 0.8 | 1.3 | 0.857 | 1.000 | 1.000 | 1.000 | |
NER | XPC | rs2279017 | 0.43 | 354 | 408 | 1.0 | 0.8 | 1.3 | 0.873 | 1.000 | 1.000 | 1.000 | |
NER | XPC | rs2228001 | 0.43 | 352 | 409 | 1.0 | 0.8 | 1.3 | 0.773 | 1.000 | 1.000 | 1.000 | |
Chinese (SBC) | |||||||||||||
BER | POLB | rs7832529 | 0.12 | 509 | 518 | 1.5 | 1.2 | 2.0 | 0.001 | 0.009 | 0.060 | 0.239 | |
NER | POLD1 | rs2244095 | 0.35 | 513 | 514 | 0.8 | 0.6 | 0.9 | 0.004 | 0.025 | 0.173 | 0.693 | |
NER | POLD1 | rs2546551 | 0.16 | 512 | 512 | 0.8 | 0.6 | 1.0 | 0.049 | 0.219 | 1.000 | 1.000 | |
NER | XPC | rs2607734 | 0.36 | 514 | 520 | 1.3 | 1.1 | 1.6 | 0.002 | 0.020 | 0.141 | 0.562 | |
NER | XPC | rs2279017 | 0.36 | 510 | 520 | 1.3 | 1.1 | 1.6 | 0.003 | 0.024 | 0.168 | 0.670 | |
NER | XPC | rs2228001 | 0.36 | 513 | 521 | 1.3 | 1.1 | 1.6 | 0.004 | 0.028 | 0.197 | 0.788 | |
NHW & Chinese (LABC & SBC) | |||||||||||||
BER | POLB | rs7832529 | 860 | 923 | 1.5 | 1.2 | 1.9 | <0.001 | 0.003 | 0.021 | 0.084 | 0.564 | |
NER | POLD1 | rs2244095 | 866 | 921 | 0.8 | 0.7 | 0.9 | 0.003 | 0.018 | 0.125 | 0.500 | 0.350 | |
NER | POLD1 | rs2546551 | 865 | 916 | 0.8 | 0.7 | 0.9 | 0.009 | 0.049 | 0.342 | 1.000 | 0.676 | |
NER | XPC | rs2607734 | 869 | 929 | 1.2 | 1.0 | 1.4 | 0.015 | 0.095 | 0.667 | 1.000 | 0.041 | |
NER | XPC | rs2279017 | 864 | 928 | 1.2 | 1.0 | 1.4 | 0.018 | 0.111 | 0.778 | 1.000 | 0.044 | |
NER | XPC | rs2228001 | 865 | 930 | 1.2 | 1.0 | 1.4 | 0.016 | 0.101 | 0.709 | 1.000 | 0.058 |
Per allele ORs and 95% CIs estimated from conditional logistic regression models assuming a log-additive mode of risk and adjusting for smoking status in reference year;
LCI = 95% lower confidence interval; UCI = 95% upper confidence interval; pcrude = unadjusted for multiple testing p-value; pACT = p-value corrected for multiple testing within gene region; ppathway = p-value corrected for multiple testing within gene region and within pathway; poverall = p-value corrected for testing across all SNPs and pathways; p-Het = LRT p-value from test of heterogeneity
Among the 469 tagSNPs investigated among the LABC and SBC combined, 24 tagSNPs showed statistically significant associations with bladder cancer (pcrude < 0.05). Only 3 tagSNPs— the same ones we observed to be associated among Shanghai Chinese from the SBCS— remained statistically significant after multiple comparisons adjustment within gene region (pACT < 0.05): one in the POLB gene (rs7832529, OR = 1.5, 95% CI = 1.2–1.9, pACT = 0.003) and two in the POLD1gene (rs2244095, OR = 0.8, 95% CI = 0.7–0.9, pACT = 0.018; rs2546551, OR = 0.8, 95% CI = 0.7–0.9, pACT = 0.049) genes (Table 2). Of these three SNPs, only one remained statistically significant when correcting for all genes within the corresponding pathway (BER), and showed a borderline significant association when correcting for all pathways considered (POLB rs7832529 pACT = 0.003; ppathway = 0.021; poverall = 0.084). None of these 3 tagSNPs showed statistically significant heterogeneity by racial groups (NHW versus Chinese); results among Chinese and NHW were of similar magnitude and direction but were statistically significant only among Chinese. Conversely, the 3 tagSNPs in the XPC gene found to be statistically significantly associated with bladder cancer risk among Chinese showed heterogeneity by race (rs2607734 heterogeneity p = 0.041; rs2279017 heterogeneity p = 0.044; rs2228001 heterogeneity p = 0.058), with the association being restricted to Chinese.
DNA repair SNPs and Smoking Interactions
We conducted gene by smoking interaction analyses among NHW and Chinese combined. None of the SNPs previously identified to associate with bladder cancer risk (Tables 2) were found to modify the risk of smoking on bladder cancer. XRCC6 (rs2284082), XPA (rs7853179), XRCC3 (rs709400), and DCLRE1C (rs1079622) were found to modify the effect of smoking across different measures of exposure, with interaction test p-values that achieved statistical significance within each gene, but not at the pathway level (Table 3). The only exception was XRCC6 SNP rs2284082 (NHEJ pathway), which showed an interaction that achieved within gene region and within pathway and overall pathway statistical significance (Table 4). Specifically, among carriers of one (CT) or two (CC) copies of the major allele C, statistically significant trends were observed for the associations between smoking pack-years, years of smoking, cigarettes per day, and smoking status, with greater strengths of association for CC carriers than CT carriers. Instead, among carriers of two copies of the minor allele T (TT), non-statistically significant positive trends, with reduced estimates, were observed (Table 4). For all smoking variables considered, except cigarettes per day, tests of interaction remained statistically significant after correction for multiple testing at the gene and pathway levels (Smoking pack-years interaction pgene = 0.003, ppathway = 0.020; years of smoking interaction pgene = 0.008, ppathway = 0.046; smoking status interaction pgene = 0.001, ppathway = 0.008) (Table 4). Test of interaction for smoking status also remained statistically significant when further correcting for the total number of DNA repair pathways investigated (smoking pack-years interaction poverall = 0.032) (Table 4).
Table 3.
Exposure | # SNPs with interaction pcrude <0.05 | Pathway | Gene | SNP | interaction pcrude | interaction pgene | interaction ppathway | interaction poverall |
---|---|---|---|---|---|---|---|---|
Years of smoking | 29 | NHEJ | XRCC6 | rs2284082 | 0.001 | 0.008 | 0.046 | 0.185 |
NER | XPA | rs7853179 | 0.002 | 0.023 | 0.164 | 0.656 | ||
HR | XRCC3 | rs709400 | 0.003 | 0.036 | 0.250 | 0.999 | ||
Pack-years of smoking | 26 | NHEJ | XRCC6 | rs2284082 | <0.001 | 0.003 | 0.020 | 0.079 |
NHEJ | DCLRE1C | rs10796227 | 0.002 | 0.033 | 0.199 | 0.794 | ||
Cigarettes per day | 8 | NHEJ | XRCC6 | rs2284082 | 0.015 | 0.093 | 0.556 | 1.000 |
Smoking Status | 35 | NHEJ | XRCC6 | rs2284082 | <0.001 | 0.001 | 0.008 | 0.034 |
HR | XRCC3 | rs709400 | 0.002 | 0.025 | 0.177 | 0.706 | ||
NER | XPA | rs7853179 | 0.003 | 0.048 | 0.338 | 1.000 | ||
NHEJ | DCLRE1C | rs10796227 | 0.004 | 0.050 | 0.302 | 1.000 |
Table 4.
Smoking variables | Cases/Controls | CC | CT | TT | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||||||
Smoking pack-yrs | CC | CT | TT | OR | LCI | UCI | p-value | OR | LCI | UCI | p-value | OR | LCI | UCI | p-value | Interaction p-values | |
|
|
|
|
||||||||||||||
Never | 67/144 | 111/174 | 54/57 | 1.0 | 1.0 | 1.0 | pcrude | 0.001 | |||||||||
< 24 pack-years | 84/112 | 105/99 | 45/45 | 1.9 | 1.3 | 2.8 | 0.001 | 1.6 | 1.2 | 2.2 | <0.001 | 1.4 | 0.9 | 2.3 | 0.151 | pgene | 0.003 |
≥ 24 pack-years | 154/91 | 173/129 | 45/42 | 4.3 | 3.0 | 6.2 | <0.001 | 2.4 | 1.9 | 3.2 | <0.001 | 1.4 | 0.9 | 2.2 | 0.193 | ppathway | 0.020 |
p for trend | <0.001 | <0.001 | 0.288 | poverall | 0.079 | ||||||||||||
Years of smoking | |||||||||||||||||
Never | 67/144 | 111/174 | 54/57 | 1.0 | 1.0 | 1.0 | pcrude | 0.001 | |||||||||
<29 | 90/109 | 95/104 | 38/36 | 1.8 | 1.2 | 2.7 | 0.003 | 1.5 | 1.1 | 2.0 | 0.007 | 1.2 | 0.7 | 2.1 | 0.417 | pgene | 0.008 |
≥29 | 148/94 | 183/124 | 52/51 | 4.4 | 3.0 | 6.4 | <0.001 | 2.6 | 2.0 | 3.4 | <0.001 | 1.5 | 1.0 | 2.4 | 0.077 | ppathway | 0.046 |
p for trend | <0.001 | <0.001 | 0.077 | poverall | 0.185 | ||||||||||||
Cigarettes per day | |||||||||||||||||
Never | 67/144 | 111/174 | 54/57 | 1.0 | 1.0 | 1.0 | pcrude | 0.015 | |||||||||
<20 | 81/84 | 95/94 | 38/41 | 2.3 | 1.5 | 3.4 | <0.001 | 1.7 | 1.3 | 2.2 | <0.001 | 1.2 | 0.8 | 2.0 | 0.405 | pgene | 0.093 |
≥20 | 157/119 | 183/134 | 52/46 | 3.5 | 2.4 | 5.0 | <0.001 | 2.3 | 1.8 | 3.0 | <0.001 | 1.5 | 1.0 | 2.4 | 0.069 | ppathway | 0.556 |
p for trend | <0.001 | <0.001 | 0.068 | poverall | 1.000 | ||||||||||||
Smoking Status | |||||||||||||||||
Never | 67/144 | 111/174 | 54/57 | 1.0 | 1.0 | 1.0 | pcrude | <0.001 | |||||||||
Former | 78/118 | 87/100 | 30/31 | 1.6 | 1.1 | 2.4 | 0.022 | 1.4 | 1.1 | 1.9 | 0.021 | 1.3 | 0.7 | 2.1 | 0.394 | pgene | 0.001 |
Current | 160/85 | 191/128 | 60/56 | 4.7 | 3.3 | 6.9 | <0.001 | 2.6 | 2.0 | 3.4 | <0.001 | 1.4 | 0.9 | 2.3 | 0.123 | ppathway | 0.008 |
p for trend | <0.001 | <0.001 | 0.125 | poverall | 0.032 |
Per allele ORs and 95% CIs estimated from conditional logistic regression models with genotype coded as log-additive, adjusting for smoking status in reference year; LCI = 95% lower confidence interval; UCI = 95% upper confidence interval; pclude = unadjusted for multiple testing p-value; pgene = p-value corrected for multiple testing within gene region; ppathway = p-value corrected for multiple testing within gene region and within pathway; poverall = p-value corrected for testing across all SNPs and pathways.
DNA repair SNPs by gender interactions
To explore possible heterogeneity of the SNP-bladder cancer associations, we conducted stratified analysis by gender among NHW, Chinese, and among both sites combined (Table 5). Among NHW males but not NHW females, we observed inverse associations for three linked LIG1 SNPs (rs2007183, rs20579, rs3730912) with bladder cancer that were statistically significant after within-gene-region correction (pACT < 0.05) and showed evidence of heterogeneity by gender (p heterogeneity < 0.05) (Table 5).
Table 5.
Males
|
Females
|
||||||||||||||||||||
Pathway | Gene | SNP | CA | CO | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | CA | CO | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | LRp |
|
|
|
|
||||||||||||||||||
NHW | |||||||||||||||||||||
NER | LIG1 | rs2007183 | 277 | 322 | 0.6 | 0.4 | 0.9 | 0.005 | 0.041 | 0.288 | 1.000 | 76 | 86 | 1.7 | 0.8 | 3.8 | 0.165 | 0.609 | 1.000 | 1.000 | 0.013 |
NER | LIG1 | rs20579 | 279 | 323 | 0.6 | 0.4 | 0.9 | 0.006 | 0.044 | 0.308 | 1.000 | 76 | 86 | 1.9 | 0.9 | 4.0 | 0.113 | 0.487 | 1.000 | 1.000 | 0.008 |
NER | LIG1 | rs3730912 | 279 | 323 | 0.6 | 0.4 | 0.9 | 0.008 | 0.055 | 0.387 | 1.000 | 76 | 86 | 1.7 | 0.7 | 4.0 | 0.230 | 0.656 | 1.000 | 1.000 | 0.027 |
Males
|
Females
|
||||||||||||||||||||
Chinese | CA | CO | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | CA | CO | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | LRp | ||
|
|
|
|||||||||||||||||||
NER | XPC | rs2607734 | 407 | 400 | 1.5 | 1.2 | 1.8 | 0.001 | 0.005 | 0.032 | 0.127 | 107 | 120 | 1.0 | 0.7 | 1.5 | 0.987 | 1.000 | 1.000 | 1.000 | 0.092 |
NER | XPC | rs2228001 | 406 | 402 | 1.4 | 1.2 | 1.8 | 0.001 | 0.008 | 0.055 | 0.219 | 107 | 119 | 1.0 | 0.7 | 1.5 | 0.991 | 1.000 | 1.000 | 1.000 | 0.107 |
NER | XPC | rs2279017 | 403 | 401 | 1.4 | 1.2 | 1.8 | 0.001 | 0.008 | 0.056 | 0.223 | 107 | 119 | 1.0 | 0.7 | 1.5 | 0.902 | 1.000 | 1.000 | 1.000 | 0.139 |
NER | XPC | rs2305843 | 406 | 401 | 1.4 | 1.1 | 1.7 | 0.004 | 0.033 | 0.227 | 0.909 | 107 | 120 | 1.0 | 0.7 | 1.4 | 0.764 | 1.000 | 1.000 | 1.000 | 0.098 |
BER | POLB | rs7832529 | 403 | 398 | 1.5 | 1.1 | 2.0 | 0.009 | 0.057 | 0.400 | 1.000 | 106 | 120 | 1.8 | 1.0 | 3.2 | 0.043 | 0.237 | 1.000 | 1.000 | 0.524 |
BER | 0GG1 | rs6809452 | 407 | 402 | 0.9 | 0.7 | 1.1 | 0.324 | 0.720 | 1.000 | 1.000 | 107 | 120 | 0.5 | 0.3 | 0.8 | 0.001 | 0.007 | 0.046 | 0.184 | 0.011 |
BER | 0GG1 | rs1052133 | 404 | 402 | 0.9 | 0.8 | 1.1 | 0.443 | 0.773 | 1.000 | 1.000 | 107 | 119 | 0.6 | 0.4 | 0.8 | 0.004 | 0.026 | 0.179 | 0.717 | 0.025 |
BER | 0GG1 | rs2072668 | 405 | 402 | 0.9 | 0.8 | 1.2 | 0.518 | 1.000 | 1.000 | 1.000 | 107 | 118 | 0.6 | 0.4 | 0.9 | 0.008 | 0.049 | 0.342 | 1.000 | 0.038 |
Males
|
Females
|
||||||||||||||||||||
NHW & Chinese | CA | CO | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | CA | CO | OR1 | LCI | UCI | pcrude | pACT | ppathway | poverall | LRp | ||
|
|
|
|||||||||||||||||||
BER | POLB | rs7832529 | 678 | 719 | 1.4 | 1.1 | 1.8 | 0.015 | 0.076 | 0.534 | 1.000 | 182 | 204 | 2.1 | 1.3 | 3.4 | 0.004 | 0.024 | 0.170 | 0.679 | 0.145 |
NER | XPC | rs2305843 | 683 | 715 | 1.3 | 1.1 | 1.6 | 0.004 | 0.030 | 0.211 | 0.845 | 183 | 204 | 1.0 | 0.7 | 1.4 | 0.948 | 1.000 | 1.000 | 1.000 | 0.131 |
NER | XPC | rs2607734 | 686 | 723 | 1.3 | 1.1 | 1.5 | 0.006 | 0.040 | 0.282 | 1.000 | 183 | 206 | 1.0 | 0.7 | 1.3 | 0.984 | 1.000 | 1.000 | 1.000 | 0.190 |
NER | XPC | rs2228001 | 683 | 725 | 1.3 | 1.1 | 1.5 | 0.006 | 0.041 | 0.290 | 1.000 | 182 | 205 | 1.0 | 0.7 | 1.3 | 0.981 | 1.000 | 1.000 | 1.000 | 0.178 |
NER | P0LD1 | rs2546551 | 683 | 714 | 0.8 | 0.6 | 0.9 | 0.007 | 0.045 | 0.314 | 1.000 | 182 | 202 | 0.9 | 0.6 | 1.3 | 0.601 | 1.000 | 1.000 | 1.000 | 0.419 |
NER | P0LD1 | rs2244095 | 683 | 718 | 0.8 | 0.6 | 0.9 | 0.009 | 0.050 | 0.347 | 1.000 | 183 | 203 | 0.8 | 0.5 | 1.1 | 0.135 | 0.390 | 1.000 | 1.000 | 0.932 |
Per allele ORs and 95% CIs estimated from conditional logistic regression models assuming a log-additive mode of risk and adjusting for smoking status in reference year; LCI = 95% lower confidence interval; UCI = 95% upper confidence interval; pcrude = unadjusted for multiple testing p-value; pACT = p-value corrected for multiple testing within gene region; ppathway = p-value corrected for multiple testing within gene region and within pathway; poverall = p-value corrected for testing across all SNPs and pathways; LRp = LRT p-value from test of heterogeneity
Among Chinese, we observed 3 tagSNPs in the OGG1 gene that showed evidence of statistically significant heterogeneity by gender. These three SNPs were inversely associated with bladder cancer risk only among females, and the associations remained statistically significant after within-gene corrections, and for one of them remained significant after pathway correction as well (rs6809452, OR = 0.5; 95% CI = 0.3–0.8, pACT = 0.007, ppathway = 0.046; rs1052133, OR = 0.6, 95% CI = 0.4–0.8, pACT = 0.026; rs2072668, OR = 0.6, 95% CI = 0.4–0.9, pACT = 0.049). Similar estimates were observed among NHW females, and among NHW and Chinese females combined, but estimates did not reach statistical significance (data not shown). We also observed that the previously observed associations of the POLB tagSNP (rs7832529) and the 3 XPC tagSNPs (rs26077734, rs2228001, rs2279017) with bladder cancer risk among all Chinese individuals combined, plus an additional new XPC tagSNP (rs2305843), seemed restricted to males, but tests of heterogeneity were not statistically significant (Table 5).
Similarly, among males in the combined study (NHW and Chinese), three XPC tagSNPs (rs2305843 rs2607734, rs2228001) were statistically significantly associated with bladder cancer risk. In addition, the previously observed association between the POLD1 tagSNPs (rs2546651, rs2244095) and bladder cancer risk among both races combined seemed restricted to males. However, for neither of these tagSNPs were tests of heterogeneity by gender statistically significant (Table 5).
Pathway analyses
We used the ARTP approach to obtain a summary p-value for the association of each gene and pathway considered in the study with bladder cancer risk (Table 6). Among NHW, only LIG1 (NER pathway) achieved gene-wide statistical significance among males. Instead, among Chinese, six genes appeared associated with susceptibility to bladder cancer achieving ARTP gene-wide significance, with four of them showing heterogeneity by gender: OGG1 (Chinese females pARTP gene = 0.015), POLB (All Chinese pARTP gene = 0.010, Chinese males pARTP gene = 0.048), RAD50 (All Chinese pARTP gene = 0.034, Chinese males pARTP gene = 0.023), POLD1 (All Chinese pARTP gene = 0.021), XPC (All Chinese pARTP gene = 0.017, Chinese males pARTP gene = 0.003) and finally XRCC6 (All Chinese pARTP gene = 0.010, Chinese females pARTP gene = 0.043). Three of these genes showed ARTP gene-wide significance when all NHW and Chinese combined: POLB (Chinese & NHW pARTP gene = 0.013), RAD50 (Chinese & NHW pARTP gene = 0.048), POLD1 (Chinese & NHW pARTP gene = 0.013), and XPC (Chinese & NHW pARTP gene = 0.045) (Table 6). When considering overall pathway associations, we only observed an association of pathway-wide significance for the NER pathway among Chinese males (pARTP pathway = 0.034), and we observed a pathway-wide ARTP p-value of borderline significance when considering all Chinese combined (pARTP pathway =0.068)(Table 6).
Table 6.
Pathway | Gene/Region | ARTP Gene p-value | ARTP Pathway p-value | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||||
NHW | Chinese | Combined | NHW | Chinese | Combined | ||||||||||
|
|
|
|
||||||||||||
BER | All | Females | Males | All | Females | Males | All | All | Females | Males | All | Females | Males | All | |
|
|
|
|
|
|
||||||||||
0.746 | 0.443 | 0.4845 | 0.356 | 0.143 | 0.329 | 0.724 | |||||||||
APEX1 | 0.926 | 0.932 | 0.898 | 0.831 | 0.920 | 0.791 | 0.926 | ||||||||
LIG3 | 0.431 | 0.061 | 0.904 | 0.834 | 0.891 | 0.767 | 0.474 | ||||||||
NEIL1 | 0.633 | 0.727 | 0.712 | 0.881 | 0.922 | 0.724 | 0.894 | ||||||||
OGG1 | 0.674 | 0.678 | 0.812 | 0.225 | 0.015 | 0.556 | 0.486 | ||||||||
PARP1 | 0.170 | 0.650 | 0.066 | 0.895 | 0.085 | 0.761 | 0.628 | ||||||||
POLB | 0.416 | 0.248 | 0.980 | 0.010 | 0.262 | 0.048 | 0.013 | ||||||||
XRCC1 | 0.736 | 0.252 | 0.828 | 0.209 | 0.887 | 0.116 | 0.694 | ||||||||
HRR | 0.554 | 0.587 | 0.784 | 0.510 | 0.772 | 0.219 | 0.676 | ||||||||
MRE11A | 0.272 | 0.239 | 0.285 | 0.805 | 0.589 | 0.849 | 0.566 | ||||||||
NBN | 0.380 | 0.310 | 0.366 | 0.471 | 0.718 | 0.651 | 0.795 | ||||||||
RAD50 | 0.591 | 0.189 | 0.871 | 0.034 | 0.824 | 0.023 | 0.048 | ||||||||
RAD51 | 0.214 | 0.923 | 0.196 | 0.930 | 0.965 | 0.970 | 0.402 | ||||||||
RAD52 | 0.967 | 0.488 | 0.959 | 0.821 | 0.622 | 0.946 | 0.935 | ||||||||
XRCC2 | 0.154 | 0.267 | 0.466 | 0.779 | 0.155 | 0.978 | 0.276 | ||||||||
XRCC3 | 0.384 | 0.872 | 0.877 | 0.321 | 0.395 | 0.255 | 0.664 | ||||||||
NER | 0.649 | 0.672 | 0.234 | 0.068 | 0.293 | 0.034 | 0.107 | ||||||||
ERCC1-ERCC2 | 0.682 | 0.824 | 0.740 | 0.133 | 0.161 | 0.193 | 0.087 | ||||||||
ERCC4 | 0.312 | 0.2105 | 0.918 | 0.069 | 0.160 | 0.267 | 0.487 | ||||||||
ERCC5 | 0.177 | 0.7625 | 0.181 | 0.332 | 0.916 | 0.462 | 0.360 | ||||||||
LIG1 | 0.139 | 0.3745 | 0.025 | 0.716 | 0.302 | 0.795 | 0.942 | ||||||||
POLD1 | 0.430 | 0.4705 | 0.315 | 0.021 | 0.057 | 0.105 | 0.013 | ||||||||
XPA | 0.956 | 0.1245 | 0.985 | 0.915 | 0.491 | 0.806 | 0.886 | ||||||||
XPC | 0.563 | 0.9705 | 0.440 | 0.017 | 0.941 | 0.003 | 0.045 | ||||||||
NHEJ | 0.598 | 0.182 | 0.698 | 0.236 | 0.206 | 0.774 | 0.397 | ||||||||
DCLRE1C | 0.975 | 0.190 | 0.7845 | 0.728 | 0.216 | 0.942 | 0.717 | ||||||||
LIG4 | 0.715 | 0.241 | 0.841 | 0.908 | 0.711 | 0.935 | 0.841 | ||||||||
PRKDC | 0.587 | 0.352 | 0.7015 | 0.789 | 0.298 | 0.840 | 0.540 | ||||||||
XRCC4 | 0.104 | 0.125 | 0.140 | 0.174 | 0.247 | 0.315 | 0.129 | ||||||||
XRCC5 | 0.768 | 0.629 | 0.678 | 0.292 | 0.333 | 0.280 | 0.595 | ||||||||
XRCC6 | 0.821 | 0.076 | 0.808 | 0.038 | 0.043 | 0.284 | 0.458 |
DISCUSSION
In this study we investigated the association between a comprehensive SNP panel that captured genetic variation in genes that play key roles in four different DNA repair pathways and bladder cancer risk. Our most consistent and key findings were an association between POLB rs7832529 and bladder cancer risk, predominantly among Chinese, an association between OGG1 rs6809452 and bladder cancer risk among Chinese women only, and an association between XPC rs2607734 and bladder cancer risk among Chinese men only. POLB and OGG1 play key roles in the BER pathway and XPC participates in the NER pathway. Analyses that summarized the effects of all SNPs within each gene, obtained using the ARTP approach for both genders combined confirmed a role for POLB in bladder cancer risk among Chinese, and also indicated associations between RAD50 (HRR pathway), POLD1 (NER pathway), XPC (NER pathway), LIG1 (NER pathway), OGG1 (BER pathway) and XRCC6 (NHEJ pathway). However, when considering estimates that summarized the effect of all genes within each of the four pathways, we observed only a statistically significant association for the NER pathway among Chinese males, and a borderline statistically significant one among all Chinese combined. When considering cigarette smoking variables we found consistent evidence that the XRCC6 rs2284082 SNP (NHEJ pathway) modified the effect of smoking. Estimates of interaction for this SNP remained statistically significant after correction for multiple testing within each gene, within the NHEJ pathway, and across all four pathways. None of the genes in the other three pathways showed strong evidence of effect modification by smoking. Altogether, these findings suggest that among Chinese, particularly men, there are bladder cancer risk factors, other than smoking, that elicit the BER and NER pathways and may play key roles in bladder cancer formation. Alternatively, they suggest that presence of these genetic variants, may predispose individuals to developing bladder cancer, independently of environmental exposures, perhaps due to loss over time of DNA repair proficiency and inability to repair DNA damage that may accumulate with age. Finally, our findings support a role for the NHEJ pathway in smoking-induced bladder cancer risk, suggesting that among all types of damage induced by tobacco carcinogens, double strand breaks seem to be the ones more detrimental for cancer risk. In support of this, two other NHEJ genes (DCLRE1C and XRCC3) were also found to modify the effect of smoking, although findings were not as significant as for XRCC6.
The number of variants and genes investigated in DNA repair pathways in association with bladder cancer risk has been limited. In collaboration with the International Consortium of Bladder Cancer Studies we previously published a meta-analysis and pooled analyses of 10 common variants in 7 genes and reported that 3 SNPs (ERCC2 rs1799793, NBN rs1805794 and XPC rs2228000) were associated with a modest increase in bladder cancer risk14. GWAS, meta-analysis of GWAS and pathway-based analysis of GWAS have identified multiple loci associated with bladder cancer susceptibility in subjects of European ancestry23–29. Whereas several SNPs located in carcinogen metabolism enzyme coding genes have achieved genome-wide significance, no SNPs located in DNA repair genes have achieved genome-wide significance to date. We summarize below what is known about the genetic regions for which we found stronger evidence of an association with bladder cancer risk (XPC, POLB, OGG1, POLD) and evidence of interaction with smoking (XRCC6).
Our pathway-based analyses point to the NER pathway as relevant for bladder cancer risk. Associations between SNPs in the XPC and POLD1 genes among Chinese seemed to be responsible for the overall observed association with this pathway. NER is involved in the repair of bulky DNA adducts, such as those induced by tobacco smoke carcinogens30. The xeroderma pigmentosum complementation group C gene (XPC) (HGNC 12816) is located on chromosome 3p25. XPC detects and binds to DNA adducts and initiates recruitment of other NER pathway proteins at the site of damage31, 32. Our individual SNP analyses and overall gene analyses suggested an association between bladder cancer risk and XPC. Pooled analyses of most available epidemiological studies with data on selected XPC polymorphisms, including ours, showed an association for XPC rs2228000 with bladder cancer risk among NHW, and no association with SNP rs222800114. In this study, we could not replicate the association with rs2228000 among NHW or Chinese; however, we report a statistically significant association between XPC rs2228001 and bladder cancer risk among Chinese males.14. The functional relevance/biological mechanism of the variant is unknown. There are two 3'UTR SNPs nearby that have been reported to affect XPC protein expression: rs2470352 and rs247045833; however, neither of these SNPs are in LD with rs2228001.
Our individual SNP analyses and overall gene analyses also indicated an association between POLD1 and bladder cancer risk, which seem stronger among men. The polymerase (DNA directed), delta 1, catalytic subunit gene (POLD) (HGNC: 9175) is located on chromosome 19q13 and encodes the catalytic and proofreading subunit of Pol δ, which has polymerase and 3′-exonuclease activity34. We report associations with bladder cancer risk for two SNPs: rs2546551, an intronic SNP, and rs2244095 SNP, which is 3'-downstream of POLD, within the Spi-B transcription factor (Spi-1/PU.1 related) gene (SPIB) (HGNC: 11242). Both SNPs are unlinked among Chinese and among NHW (HapMap CHBJPT r2=0.22, D'=0.93; CEU r2=0.12, D'=1.00). These SNPs are not linked with previously SNPs investigated in relation to bladder cancer risk, for which no associations were reported35–37.
We found that SNP rs7832529 in POLB associated with bladder cancer risk, mostly among Chinese. Summary estimates at the gene level using ARTP supported this finding. The polymerase (DNA directed), beta gene (POLB) (HGNC: 9174) is located on chromosome 8p11 and encodes a DNA polymerase involved in short patch and long patch BER38. Bladder cancer tumors and cell lines frequently encounter deletions in chromosomal region 8p, with 8p11–12 being one of the affected regions39. Located 3'-downstream from POLB, SNP rs7832529 is actually located within the solute carrier family 20 (phosphate transporter), member 2 gene (SLC20A2) (HGNC: 10947). To our knowledge, SLC20A2 has not been linked with bladder cancer. Several other POLB SNPs have been reported to be associated with bladder cancer risk among Caucasians, but neither are in LD with rs783252937, 40. It remains to be determined whether rs7832529 is tagging a causal SNP in POLB or SLC20A2.
We also report that three OGG1 SNPs (rs2072668 rs6809452 and rs1052133) were inversely associated with bladder cancer risk among Chinese females, with a stronger association for rs6809452. The 8-oxoG DNA glycosylase1 gene (OGG1) (HGNC: 12816) is located on chromosome 3p2641. The OGG1 protein participates in the removal of 8-oxoguanine (8-oxoG) DNA damage that can result from ROS exposure. The intronic OGG1 rs2072668 and rs6809452 SNPs were in strong LD with the non-synonymous and putative functional OGG1 Ser326Cys SNP (rs1052133) (HapMap CHBJPT r2=0.98, D'=1.00 for rs2072668 and r2=0.88, D'=1.00 for rs6809452). SNP rs6809452, for which we found the strongest association, is actually an intronic SNP within the transcriptional adapter 3-like gene (TADA3L) gene. The OGG1 Ser326Cys rs1052133 Cys allele has been reported to code for a protein with decreased ability to repair oxidative DNA damage42–46. A meta-analysis of various cancers reported Ser326Cys was significantly associated with overall cancer risk and lung cancer risk, but was not associated with bladder cancer risk47. Three epidemiological studies have reported associations between this SNP and bladder cancer risk among Caucasians, with stronger associations among smokers35–37.
Finally, we observed strong evidence that one SNP in the XRCC6 gene, rs22284082, modified the effect of cigarette smoking. We found that among carriers of one or two copies of the C allele (major allele) there was a stronger and more significant association with tobacco smoking that among carriers of two copies of the T allele. The X-ray repair complementing defective repair in Chinese hamster cells 6 gene (XRCC6) (HGNC: 4055) is on chromosome region 22q13. SNP rs22284082 is located 3'-downstream from XRCC6 and it maps to the sterol regulatory element binding transcription factor 2 gene (SREBF2) (HGNC: 11290), in intron 1. SRBF2 encodes a transcription factor SREBP-2, a basic helix-loop-helix-leucine zipper protein that can stimulate transcription of sterol regulated genes and monitor lipid homeostasis48. In addition, SREBP-2 can also regulate autophagy related genes in times of nutrient depletion49. SREBF2 has not been investigated in relation with bladder cancer; however, it has been reported to be involved in the loss of sterol feedback regulation in cancer cells50. It remains to be determined if the interaction with smoking we see for this SNP is capturing an effect of a causal SNP in XRCC6 or SREBF2.
Our study had several strengths. Among them, was the use of two population-based case-control studies conducted in parallel in two world regions with contrasting bladder cancer incidence, using comparable instruments to assess smoking exposure. Another one is the use of a comprehensive tagSNP approach that captured 85–100% genetic variation in genes that play key roles in four major DNA repair pathway, with appropriate consideration of multiple testing. Although we recognize that our tagSNP selection was done before the release of the 1000 genomes project, which includes rare variants. Therefore, compared to this reference database, our overall genetic coverage would be lower. Finally, given that most studies on DNA repair susceptibility genes and bladder cancer have been conducting among NHW, our study contributes novel data about genetic risk factors among Chinese. Among the limitations of our study we include the fact that not all DNA repair genes from each pathway were captured, albeit all those that play essential roles were included, and the fact that we were underpowered to explore higher order interactions between genes and exposures. Lastly, in spite of our approaches for multiple testing correction, we cannot discard the possibility that some of our findings might be false positives. Replication in other studies will help confirm our findings.
In conclusion, we found support that two regions that map close to or within BER genes (POLB, OGG1), and one region in an NER gene (XPC) are associated with bladder cancer risk, primarily among Chinese. Given that these associations were not modified by smoking, they suggest that there are other environmental factors that elicit the BER and NER pathways and might be relevant bladder cancer risk factors. We also find evidence that one SNP that tags both the XRCC6 and SREBF2 genes, strongly modifies the association between bladder cancer risk and tobacco smoke. Given the role XRCC6 plays in the NHEJ pathway, this finding suggest that tobacco smoking may induce bladder cancer through the formation of double strand breaks. Further investigation in independent study populations will help confirm these findings, and guide future studies to identify the causal variants responsible for these associations, and all the relevant exposures that elicit the action of these DNA repair pathways.
Supplementary Material
NOVELTY AND IMPACT.
We conducted comprehensive analyses of genetic variation in 28 genes that participate in four DNA repair pathways. Our findings suggest that among Chinese there are environmental factors, other than smoking, that elicit the BER and NER pathways and may contribute to bladder cancer formation. Moreover, our gene by environment interaction analyses including non-Hispanic whites and Chinese suggest that double strand breaks might be the most detrimental type of tobacco-induced DNA damage for bladder cancer formation.
Table 1.
Los Angeles County |
Shanghai |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Cases n=456 | Controls n=480 | Cases n=532 | Controls n=524 | |||||||
Mean age at enrollment (SD) | 56 | (±7) | 56 | (±8) | 63 | (±10) | 64 | (±10) | ||
Age at enrollment (y) | ||||||||||
≤45 | 51 | (11%) | 62 | (13%) | 51 | (10%) | 43 | (8%) | ||
45–49 | 54 | (12%) | 57 | (12%) | 30 | (6%) | 17 | (3%) | ||
50–54 | 83 | (18%) | 93 | (19%) | 38 | (7%) | 25 | (5%) | ||
55–59 | 138 | (30%) | 128 | (27%) | 43 | (8%) | 63 | (12%) | ||
60–64 | 129 | (28%) | 104 | (22%) | 137 | (26%) | 116 | (22%) | ||
>65 | 1 | (0%) | 35 | (7%) | <0.001 | 233 | (44%) | 260 | (50%) | 0.016 |
Gender | ||||||||||
Male | 357 | (78%) | 374 | (78%) | 421 | (79%) | 404 | (77%) | ||
Female | 99 | (22%) | 106 | (22%) | 0.890 | 111 | (21%) | 120 | (23%) | 0.424 |
Smoking status | ||||||||||
Never | 83 | (18%) | 183 | (38%) | 178 | (33%) | 233 | (44%) | ||
Former | 173 | (38%) | 212 | (44%) | 75 | (14%) | 84 | (16%) | ||
Current | 200 | (44%) | 85 | (18%) | <0.001 | 279 | (52%) | 207 | (40%) | <0.001 |
Smoking intensity (cigarettes/day) | ||||||||||
Never | 83 | (18%) | 183 | (38%) | 178 | (33%) | 233 | (44%) | ||
<20 | 75 | (16%) | 88 | (18%) | 164 | (31%) | 155 | (30%) | ||
≥20 | 298 | (65%) | 209 | (44%) | <0.001 | 190 | (36%) | 136 | (26%) | <0.001 |
Smoking duration (years) | ||||||||||
Never | 83 | (18%) | 183 | (38%) | 178 | (33%) | 233 | (45%) | ||
<29 | 162 | (36%) | 190 | (40%) | 106 | (20%) | 101 | (19%) | ||
>29 | 211 | (46%) | 107 | (22%) | <0.001 | 248 | (47%) | 190 | (36%) | 0.001 |
Pack-years of smoking | ||||||||||
Never | 83 | (18%) | 183 | (38%) | 178 | (33%) | 233 | (44%) | ||
> 24 pack-years | 116 | (25%) | 151 | (31%) | 155 | (29%) | 142 | (27%) | ||
≥ 24 pack-years | 257 | (56%) | 146 | (30%) | <0.001 | 199 | (37%) | 149 | (28%) | 0.001 |
ACKNOWLEDGMENTS
The authors thank Ms. Susan Roberts for oversight of study enrollment, Ms. Peggy Wan for data analysis and management, and Dr. Mimi C. Yu and Dr. Ronald K. Ross for their efforts in starting the LABC and SBC studies, and feedback in the design of the current study.
Grant support: This research was supported by grants from the National Cancer Institute (1P01CA86871, 1R01CA065726, 1R01CA114665 and P30CA014089). Roman Corral received support from NIH grant T32GM067587. Drs. Stern and Thomas received support from grant 5P30 ES07048 from NIEHS. Dr. Gago-Dominguez received support from FIS Intrasalud (PS09/02368) and the Botin Foundation. Drs. Thomas, Conti, Lewinger, and Cortessis received support from NIH grant 1R01 ES019876. P30CA014089 from the National Cancer Institute
Abbreviations
- (BER)
Base excision repair
- (CI)
confidence interval
- (df)
degrees of freedom
- (DNA)
deoxyribonucleic acid
- (HRR)
homologous recombination repair
- (NHW)
non-Hispanic White
- (NOC)
N-nitroso compound
- (NER)
nucleotide excision repair
- (NHEJ)
non-homologous end-joining
- (OR)
odds ratio
- ROS
reactive oxygen species
- SNP
single nucleotide polymorphism
- tagSNP
haplotype tagging SNP
REFERENCES
- 1.Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93. doi: 10.1007/s00345-009-0383-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Liu L, Zhang J, Deapen D, Bernstein L, Ross RK. Cancer in Los Angeles County: Incidence and Mortality by Race/Ethnicity 1988–2000. University of Southern California; 2003. [Google Scholar]
- 3.Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas D. Cancer Incidence in Five Continents. Volume VIII. International Agency for Research on Cancer; Lyon: 2002. IARC Scientific Publications No. 155. [Google Scholar]
- 4.Lerner SP, Schoenberg MP, Sternberg CN. Textbook of bladder cancered. Taylor & Francis; Abingdon, Oxon; Boca Raton: 2006. [Google Scholar]
- 5.IARC Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans . Tobacco smokinged. World Health Organization, International Agency for Research on Cancer; Lyon: 1986. International Agency for Research on Cancer. [Google Scholar]
- 6.Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA : the journal of the American Medical Association. 2011;306:737–45. doi: 10.1001/jama.2011.1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nat Clin Pract Urol. 2007;4:205–17. doi: 10.1038/ncpuro0760. [DOI] [PubMed] [Google Scholar]
- 8.Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer. 2001;91:575–9. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1092>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- 9.Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, Sithisarankul P, Strickland P. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer. 1996;65:314–6. doi: 10.1002/(SICI)1097-0215(19960126)65:3<314::AID-IJC6>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
- 10.Pryor WA, Hales BJ, Premovic PI, Church DF. The radicals in cigarette tar: their nature and suggested physiological implications. Science. 1983;220:425–7. doi: 10.1126/science.6301009. [DOI] [PubMed] [Google Scholar]
- 11.Maeda H, Sawa T, Yubisui T, Akaike T. Free radical generation from heterocyclic amines by cytochrome b5 reductase in the presence of NADH. Cancer Lett. 1999;143:117–21. doi: 10.1016/s0304-3835(99)00139-1. [DOI] [PubMed] [Google Scholar]
- 12.Burger MS, Torino JL, Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl. Environ Mol Mutagen. 2001;38:1–11. doi: 10.1002/em.1044. [DOI] [PubMed] [Google Scholar]
- 13.Lin J, Kadlubar FF, Spitz MR, Zhao H, Wu X. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1832–6. doi: 10.1158/1055-9965.EPI-04-0902. [DOI] [PubMed] [Google Scholar]
- 14.Stern MC, Lin J, Figueroa JD, Kelsey KT, Kiltie AE, Yuan JM, Matullo G, Fletcher T, Benhamou S, Taylor JA, Placidi D, Zhang ZF, et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 2009;69:6857–64. doi: 10.1158/0008-5472.CAN-09-1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J. Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer. 2012;118:205–15. doi: 10.1002/cncr.26224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst. 2001;93:538–45. doi: 10.1093/jnci/93.7.538. [DOI] [PubMed] [Google Scholar]
- 17.Tao L, Xiang YB, Wang R, Nelson HH, Gao YT, Chan KK, Yu MC, Yuan JM. Environmental tobacco smoke in relation to bladder cancer risk--the Shanghai bladder cancer study [corrected] Cancer Epidemiol Biomarkers Prev. 2010;19:3087–95. doi: 10.1158/1055-9965.EPI-10-0823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J Cancer. 2000;85:358–63. doi: 10.1002/(sici)1097-0215(20000201)85:3<358::aid-ijc11>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- 19.Edlund CK, Lee WH, Li D, Van Den Berg DJ, Conti DV. Snagger: a user-friendly program for incorporating additional information for tagSNP selection. BMC Bioinformatics. 2008;9:174. doi: 10.1186/1471-2105-9-174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques. 2002;(Suppl):56–8. 60–1. [PubMed] [Google Scholar]
- 21.Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet. 2007;81:1158–68. doi: 10.1086/522036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Yu K, Li Q, Bergen AW, Pfeiffer RM, Rosenberg PS, Caporaso N, Kraft P, Chatterjee N. Pathway analysis by adaptive combination of P-values. Genet Epidemiol. 2009;33:700–9. doi: 10.1002/gepi.20422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M, Chatterjee N, Kogevinas M, Baris D, Thun M, Hall JL, De Vivo I, Albanes D, et al. Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum Mol Genet. 2012;21:1918–30. doi: 10.1093/hmg/ddr619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42:978–84. doi: 10.1038/ng.687. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Besenbacher S, Gudbjartsson D, Stacey SN, et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet. 2011;20:4268–81. doi: 10.1093/hmg/ddr303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Menashe I, Figueroa JD, Garcia-Closas M, Chatterjee N, Malats N, Picornell A, Maeder D, Yang Q, Prokunina-Olsson L, Wang Z, Real FX, Jacobs KB, et al. Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. PloS one. 2012;7:e29396. doi: 10.1371/journal.pone.0029396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, Gudmundsson J, Jakobsdottir M, Bergthorsson JT, Sigurdsson A, Blondal T, Witjes JA, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008;40:1307–12. doi: 10.1038/ng.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, Gudbjartsson DF, Stacey SN, Gudmundsson J, Zanon C, Kostic J, Masson G, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet. 2010;42:415–9. doi: 10.1038/ng.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, et al. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011;20:4282–9. doi: 10.1093/hmg/ddr342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33. doi: 10.1038/35094000. [DOI] [PubMed] [Google Scholar]
- 31.Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP, Hanaoka F, Bootsma D, Hoeijmakers JH. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell. 1998;2:223–32. doi: 10.1016/s1097-2765(00)80132-x. [DOI] [PubMed] [Google Scholar]
- 32.Araki M, Masutani C, Takemura M, Uchida A, Sugasawa K, Kondoh J, Ohkuma Y, Hanaoka F. Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair. J Biol Chem. 2001;276:18665–72. doi: 10.1074/jbc.M100855200. [DOI] [PubMed] [Google Scholar]
- 33.Qiao B, Scott GB, Elliott F, Vaslin L, Bentley J, Hall J, Bishop D, Knowles MA, Kiltie AE. Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients. BMC medical genetics. 2011;12:84. doi: 10.1186/1471-2350-12-84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Burgers PM. Polymerase dynamics at the eukaryotic DNA replication fork. J Biol Chem. 2009;284:4041–5. doi: 10.1074/jbc.R800062200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464–79. doi: 10.1086/500848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2007;16:84–91. doi: 10.1158/1055-9965.EPI-06-0712. [DOI] [PubMed] [Google Scholar]
- 37.Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Tardon A, Serra C, Carrato A, Garcia-Closas R, et al. Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet. 2007;121:233–42. doi: 10.1007/s00439-006-0294-y. [DOI] [PubMed] [Google Scholar]
- 38.Dogliotti E, Fortini P, Pascucci B, Parlanti E. The mechanism of switching among multiple BER pathways. Prog Nucleic Acid Res Mol Biol. 2001;68:3–27. doi: 10.1016/s0079-6603(01)68086-3. [DOI] [PubMed] [Google Scholar]
- 39.Wagner U, Bubendorf L, Gasser TC, Moch H, Gorog JP, Richter J, Mihatsch MJ, Waldman FM, Sauter G. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol. 1997;151:753–9. [PMC free article] [PubMed] [Google Scholar]
- 40.Michiels S, Laplanche A, Boulet T, Dessen P, Guillonneau B, Mejean A, Desgrandchamps F, Lathrop M, Sarasin A, Benhamou S. Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. Carcinogenesis. 2009;30:763–8. doi: 10.1093/carcin/bgp046. [DOI] [PubMed] [Google Scholar]
- 41.Boiteux S, Radicella JP. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys. 2000;377:1–8. doi: 10.1006/abbi.2000.1773. [DOI] [PubMed] [Google Scholar]
- 42.Lee AJ, Hodges NJ, Chipman JK. Interindividual variability in response to sodium dichromate-induced oxidative DNA damage: role of the Ser326Cys polymorphism in the DNA-repair protein of 8-oxo-7,8-dihydro-2'-deoxyguanosine DNA glycosylase 1. Cancer Epidemiol Biomarkers Prev. 2005;14:497–505. doi: 10.1158/1055-9965.EPI-04-0295. [DOI] [PubMed] [Google Scholar]
- 43.Yamane A, Kohno T, Ito K, Sunaga N, Aoki K, Yoshimura K, Murakami H, Nojima Y, Yokota J. Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis. 2004;25:1689–94. doi: 10.1093/carcin/bgh166. [DOI] [PubMed] [Google Scholar]
- 44.Hill JW, Evans MK. Dimerization and opposite base-dependent catalytic impairment of polymorphic S326C OGG1 glycosylase. Nucleic Acids Res. 2006;34:1620–32. doi: 10.1093/nar/gkl060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Sidorenko VS, Grollman AP, Jaruga P, Dizdaroglu M, Zharkov DO. Substrate specificity and excision kinetics of natural polymorphic variants and phosphomimetic mutants of human 8-oxoguanine-DNA glycosylase. Febs J. 2009;276:5149–62. doi: 10.1111/j.1742-4658.2009.07212.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Kershaw RM, Hodges NJ. Repair of oxidative DNA damage is delayed in the Ser326Cys polymorphic variant of the base excision repair protein OGG1. Mutagenesis. 2012;27:501–10. doi: 10.1093/mutage/ges012. [DOI] [PubMed] [Google Scholar]
- 47.Wei B, Zhou Y, Xu Z, Xi B, Cheng H, Ruan J, Zhu M, Hu Q, Wang Q, Wang Z, Yan Z, Jin K, et al. The effect of hOGG1 Ser326Cys polymorphism on cancer risk: evidence from a meta-analysis. PLoS One. 2011;6:e27545. doi: 10.1371/journal.pone.0027545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–31. doi: 10.1172/JCI15593. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Seo YK, Jeon TI, Chong HK, Biesinger J, Xie X, Osborne TF. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab. 2011;13:367–75. doi: 10.1016/j.cmet.2011.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer. 2001;91:41–5. doi: 10.1002/1097-0215(20010101)91:1<41::aid-ijc1009>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.